Anixa Biosciences (ANIX) to Release Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is expected to post its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Anixa Biosciences to post earnings of ($0.10) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $2.84 on Monday. The stock has a fifty day simple moving average of $2.78 and a two-hundred day simple moving average of $3.03. The firm has a market capitalization of $91.44 million, a PE ratio of -7.28 and a beta of 0.86. Anixa Biosciences has a 52-week low of $2.07 and a 52-week high of $4.20.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction on Wednesday, January 15th. The shares were acquired at an average price of $2.23 per share, with a total value of $95,890.00. Following the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. The trade was a 8.32 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lewis H. Titterton, Jr. bought 10,000 shares of the stock in a transaction dated Friday, January 17th. The shares were purchased at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the transaction, the director now directly owns 922,334 shares in the company, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 75,289 shares of company stock valued at $177,021 in the last 90 days. Insiders own 25.30% of the company’s stock.

Wall Street Analysts Forecast Growth

ANIX has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, February 18th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.